In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Quiz|Articles|October 2, 2026
OncLive Weekly News Quiz (10/2/2026): Did You Miss Crucial Lung Cancer, Breast Cancer, MDS, and PTLD Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
A new drug application (NDA) has been submitted to the FDA seeking the approval of savolitinib (Orpathys) plus osimertinib (Tagrisso) for patients with locally advanced or metastatic, EGFR-mutated non–small cell lung cancer (NSCLC) with MET overexpression or amplification following progression on EGFR TKI therapy, supported by data from the phase 3 SAFFRON trial (NCT05261399). Approximately what proportion of tumors develop high MET overexpression or amplification after progression on third-generation EGFR TKIs?
Advertisement
Related to this article
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
3
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
4
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
5